Dihydroartemisinin/piperaquine

Drug Profile

Dihydroartemisinin/piperaquine

Alternative Names: Artekin; Eurartekin; Eurartesim; Piperaquine/dihydroartemisinin

Latest Information Update: 03 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chongqing Holley; Medicines for Malaria Venture; sigma-tau SpA; University of Oxford
  • Developer Medicines for Malaria Venture; sigma-tau SpA
  • Class Antimalarials; Artemisinins; Piperazines; Quinolines; Sesquiterpenes
  • Mechanism of Action Free radical stimulants; Hemozoin inhibitors; Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malaria
  • New Molecular Entity No

Highest Development Phases

  • Marketed Malaria

Most Recent Events

  • 03 Dec 2015 The Medicines for Malaria Venture announces intention to submit the dispersible paediatric formulation to the EMA in the second quarter of 2015
  • 08 Jul 2015 Sigma-tau SpA completes its phase II trial in Malaria (In infants) in Tanzania, Congo, Mozambique, Gambia and Burkina Faso (NCT01992900)
  • 02 Jul 2015 Dihydroartemisinin/piperaquine licensed to Pierre Fabre in Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Chad, Congo, Democratic Republic of the Congo, Ethiopia, Gabon, Ghana, Guinea, Ivory Coast, Kenya, Liberia, Madagascar, Malawi, Mali, Mauritania, Mozambique, Namibia, Niger, Nigeria, Senegal, Sierra Leone, Swaziland, Tanzania, Togo, Uganda, Zambia and Zimbabwe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top